A Single Center 11 Year Experience with 202 Pancreas Transplants: Evolving Trends
Journal: Journal of Diabetes Research and Therapy (Vol.1, No. 3)Publication Date: 2015-11-06
Authors : Jeffrey Rogers Alan C Farney Giuseppe Orlando Samy S Iskandar William Doares Michael D. Gautreaux Scott Kaczmorski Amber Reeves-Daniel Amudha Palanisamy et al.;
Page : 1-11
Keywords : Alemtuzumab; Mycophenolate mofetil; Pancreas transplantation; Portal-enteric; Rabbit anti-thymocyte globulin; Simultaneous kidney-pancreas transplantation; Steroid elimination; Surveillance biopsy; Tacrolimus;
Abstract
A single center experience with pancreas transplantation (PTx) over an 11+ year period is reviewed. Methods: We retrospectively studied outcomes in 202 consecutive PTxs in 192 patients at our center. All patients received either rATG or alemtuzumab (Alem) induction with tacrolimus/MMF and tapered steroids or early withdrawal. 179 PTxs (89%) were performed with portal-enteric and 23 with systemic-enteric drainage. Results: From 11/01 to 3/13, we performed 162 simultaneous kidney-PTxs (SKPT), 35 sequential PTxs after kidney (PAK), and 5 PTx alone (PTA; 40 solitary PTxs [SPT]). 186 PTxs (92%) were primary and 16 pancreas retransplants. With a mean follow-up of 5.5 years, overall patient (87% SKPT versus 87.5% SPT), kidney (74% SKPT versus 82.5% SPT) and pancreas graft survival (both 65%) rates were comparable. Causes of PTx loss were also similar between SKPT and SPT; the rates of early thrombosis were 8.6% and 5%, respectively. Acute rejection rates were similar between groups (SKPT 29% versus SPT 26%, p=NS). A randomized trial of Alem versus rATG induction in SKPT demonstrated lower rates of acute rejection and infection in the Alemgroup; consequently, Alem induction has been used exclusively in all PTxs since 2009. Early steroid elimination has been feasible in most patients. Surveillance PTx biopsy-directed immunosuppression has contributed to equivalent long-term outcomes in SKPT and SPT. Good results have been achieved in African-American patients and in patients with a type 2 diabetes phenotype. Conclusions: Excellent 5 year outcomes following PTx can be achieved as >86% of patients are alive, >87% of surviving patients are dialysisfree, 80% of surviving patients remain insulin-free, and 88% of surviving patients have detectable C-peptide levels.
Other Latest Articles
- The Impact of Knowledge and Attitudes on Self-management of People with Type 2 Diabetes Mellitus
- Histone Protein Glycation and Diabetes
- Program ACTIVE II: Design and Methods for a Multi-Center Community-Based Depression Treatment for Rural and Urban Adults with Type 2 Diabetes
- Modulator of Diabetes and Metabolic Syndrome: Silent Proteins, newer Insights
- Overview of Sodium-Glucose Co-Transport Inhibitors
Last modified: 2020-08-10 23:56:51